Please let me save you $0.295/sh, page-24

It seems that there are several issues impacting trust in the company's management, not so much in the business model (as Glaucus' claims have been responded to by management in great detail). The mistrust of management has been caused firstly by Frank Wilson's resignation and announcement that he's seeking a change of control of the company (but has yet to come out with any credible details), and the announcement made by the board a few days ago, that they had just been made aware of the fact that one customer, Galderma, has terminated a supply and licensing agreement with a subsidiary of Quintis, Santalis.

This admission by the board is perceived as an indication of very poor management and possibly a dereliction of their duty to shareholders, and the termination itself has been touted as proof of Quintis' inability to meet its sales and earnings forecasts.

However (in my humble opinion only), many of the anti-Quintis posters here ignore (or are unaware of) the fact that under the original agreement with Galderma, no specific supply quantities nor a commitment to reorder had been agreed upon; that Galderma has discontinued the product for which it sourced sandalwood oil from Santalis, and therefore probably doesn't need to buy any more oil; and furthermore, that under the termination terms, Galderma has RETAINED the option to REINSTATE the license and supply arrangements on or before July 1 , 2017. Another fact that is being ignored is that Quintis has other customers as well as other revenue sources, such as fees from managing plantations for other parties; that the market for sandalwood products is growing and suffering from shortages, which Quintis is well placed to provide; and that the company is working on developing new markets for its product.

IMHO, while the breakdown in communications between Santalis and the Quintis board indicates there is much to be improved in the area of governance, and while the loss of a customer has always a negative impact on revenues, these two issues have been blown beyond all proportion by those shorters whose interest it is to create a "run on the bank" in order to promote their own interests.

At the moment, the company seems to be circled by a few other vultures, such as the lawyers who are already collecting expressions of interest in a class action against the company. So there's a lot of panic and nearly complete opaqueness surrounding this bungee-jump of the share price since the first negative report by Glaucus was published.
I, personally, am able to live with the losses I made so far. I'm waiting to see if the company finally comes out from behind the curtain and gives its shareholders some information on what its true prospects are (seeing as Julius Matthys has been working on his review of Quintis operations and prospects for nearly a month now, surely he has something to tell us beyond one terminated supply agreement from six months ago).

So, if I may be so bold as to advise a non-holder what to do, my advice is to not get in at the moment as there is not enough information nor clarity to make any informed decision, other than a speculative gamble. I, as a holder, continue to hold for the time being and assess the situation as it unfolds.